{
  "id": "56c1f043ef6e394741000057",
  "type": "list",
  "question": "Which receptors are bound by Tasimelteon?",
  "ideal_answer": "Tasimelteon (HETLIOZ\u2122) is an orally bioavailable agonist of the melatonin MT1 and MT2 receptors that has been approved in the US for the treatment of non-24-hour sleep-wake disorder.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/25423562",
    "http://www.ncbi.nlm.nih.gov/pubmed/25534555",
    "http://www.ncbi.nlm.nih.gov/pubmed/24610704",
    "http://www.ncbi.nlm.nih.gov/pubmed/25207602",
    "http://www.ncbi.nlm.nih.gov/pubmed/19579175",
    "http://www.ncbi.nlm.nih.gov/pubmed/24228714",
    "http://www.ncbi.nlm.nih.gov/pubmed/25422900",
    "http://www.ncbi.nlm.nih.gov/pubmed/20945020"
  ],
  "snippets": [
    {
      "text": "We present here data on the in vitro binding affinity of tasimelteon for both human melatonin receptors MT1 and MT2, as well as the extended screen of other receptors and enzymes. Results indicate that tasimelteon is a potent Dual Melatonin Receptor Agonist (DMRA) with 2.1-4.4 times greater affinity for the MT2 receptor believed to mediate circadian rhythm phase-shifting (Ki = 0.0692 nM and Ki = 0.17 nM in NIH-3T3 and CHO-K1 cells, respectively), than for the MT1 receptor (Ki = 0.304 nM and Ki = 0.35 nM, respectively).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25534555",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The drugs covered target GABAA (zaleplon-CR, lorediplon, EVT-201), orexin (filorexant, MIN-202), histamine-H1 (LY2624803), serotonin 5-HT2A (ITI-007), melatonin/serotonin5-HT1A (piromelatine) and melatonin (indication expansions of prolonged-release melatonin and tasimelteon for pediatric sleep and circadian rhythm disorders) receptors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25423562",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Several melatonin receptors agonists (ramelteon, prolonged-release melatonin, agomelatine and tasimelteon) have recently become available for the treatment of insomnia, depression and circadian rhythms sleep-wake disorders. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25207602",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tasimelteon (HETLIOZ\u2122) is an orally bioavailable agonist of the melatonin MT1 and MT2 receptors that has been approved in the US for the treatment of non-24-hour sleep-wake disorder. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24610704",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Numerous physiological functions of the pineal gland hormone melatonin are mediated via activation of two G-protein-coupled receptors, MT1 and MT2. The melatonergic drugs on the market, ramelteon and agomelatine, as well as the most advanced drug candidates under clinical evaluation, tasimelteon and TIK-301, are high-affinity nonselective MT1/MT2 agonists. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24228714",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A new melatonin 1 and melatonin 2 agonist tasimelteon improves sleep in these patients, resetting their circadian sleep-wake clocks.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25422900",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A general suitability in mitigating other symptoms of major depressive disorder cannot be deduced from the actions of tasimelteon via the melatonin receptors MT1 and MT2.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19579175",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tasimelteon (HETLIOZ\u2122) is an orally bioavailable agonist of the melatonin MT1 and MT2 receptors that has been approved in the US for the treatment of non-24-hour sleep-wake disorder.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24610704",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ramelteon and tasimelteon are new chrono-hypnotic agents, selective for melatonin MT1 and MT2 receptors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20945020",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Results indicate that tasimelteon is a potent Dual Melatonin Receptor Agonist (DMRA) with 2.1-4.4 times greater affinity for the MT2 receptor believed to mediate circadian rhythm phase-shifting (Ki = 0.0692 nM and Ki = 0.17 nM in NIH-3T3 and CHO-K1 cells, respectively), than for the MT1 receptor (Ki = 0.304 nM and Ki = 0.35 nM, respectively). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25534555",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A general suitability in mitigating other symptoms of major depressive disorder cannot be deduced from the actions of tasimelteon via the melatonin receptors MT1 and MT2. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19579175",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We present here data on the in vitro binding affinity of tasimelteon for both human melatonin receptors MT1 and MT2, as well as the extended screen of other receptors and enzymes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25534555",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Results indicate that tasimelteon is a potent Dual Melatonin Receptor Agonist (DMRA) with 2.1-4.4 times greater affinity for the MT2 receptor believed to mediate circadian rhythm phase-shifting (Ki = 0.0692 nM and Ki = 0.17 nM in NIH-3T3 and CHO-K1 cells, respectively), than for the MT1 receptor (Ki = 0.304 nM and Ki = 0.35 nM, respectively).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25534555",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We present here data on the in vitro binding affinity of tasimelteon for both human melatonin receptors MT1 and MT2, as well as the extended screen of other receptors and enzymes. Results indicate that tasimelteon is a potent Dual Melatonin Receptor Agonist (DMRA) with 2.1-4.4 times greater affinity for the MT2 receptor believed to mediate circadian rhythm phase-shifting (Ki = 0.0692 nM and Ki = 0.17 nM in NIH-3T3 and CHO-K1 cells, respectively), than for the MT1 receptor (Ki = 0.304 nM and Ki = 0.35 nM, respectively).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25534555",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Results indicate that tasimelteon is a potent Dual Melatonin Receptor Agonist (DMRA) with 2.1-4.4 times greater affinity for the MT2 receptor believed to mediate circadian rhythm phase-shifting (Ki = 0.0692 nM and Ki = 0.17 nM in NIH-3T3 and CHO-K1 cells, respectively), than for the MT1 receptor (Ki = 0.304 nM and Ki = 0.35 nM, respectively). Tasimelteon was also shown to have no appreciable affinity for more than 160 other pharmacologically relevant receptors and several enzymes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25534555",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Hetlioz(\u00ae) (tasimelteon) is the first approved treatment in the United States for Non-24-Hour Sleep-Wake Disorder (Non-24). We present here data on the in vitro binding affinity of tasimelteon for both human melatonin receptors MT1 and MT2, as well as the extended screen of other receptors and enzymes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25534555",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Results indicate that tasimelteon is a potent Dual Melatonin Receptor Agonist (DMRA) with 2.1-4.4 times greater affinity for the MT2 receptor believed to mediate circadian rhythm phase-shifting (Ki = 0.0692 nM and Ki = 0.17 nM in NIH-3T3 and CHO-K1 cells, respectively), than for the MT1 receptor (Ki = 0.304 nM and Ki = 0.35 nM, respectively).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25534555",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We present here data on the in vitro binding affinity of tasimelteon for both human melatonin receptors MT1 and MT2, as well as the extended screen of other receptors and enzymes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25534555",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "MT1, MT2"
}